

12th December 2024

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Thursday 28th November 2024. I am pleased to confirm the following.

How many early-stage (non-metastatic or Stages 2-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Chemotherapy
- Radiotherapy
- Chemotherapy AND Radiotherapy

Under section 12(1) of the FOIA, MKUH is not obliged to comply with an information request where to do so would exceed the appropriate limit. We estimate that the cost of locating and collating any relevant information and extracting the information to meet your request would exceed the appropriate limit of £450 specified in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. We are therefore unable to comply with it. The £450 limit is based on work being carried out at a rate of £25 per hour, which equates to 18 hours of work per request. The cost of locating, retrieving and extracting information can be included in the costs for these purposes.

If you would like to revise your request, we will happily investigate it for you.

Question Two:

How many patients has your Trust treated in total in the past 3 months for

- Stage 2 Non Small Cell Lung Cancer 3
- Stage 3 Non Small Cell Lung Cancer 8

Question Three:

How many patients who received Pembrolizumab for Non Small Cell Lung Cancer (NSCLC) (any stage) in the last 3 months, received:

Pembrolizumab Monotherapy

Treatment every 3 weeks (200mg, Q3W) 0

Treatment every 6 weeks (400mg, Q6W) 9

Pembrolizumab in combination with chemotherapy

Treatment every 3 weeks (200mg, Q3W) 6

Treatment every 6 weeks (400mg, Q6W) 0

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Information Governance Administrator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.